Allergy

The information on this site is intended for health care professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Prescribing Information Patient Information Return to singulair.com

SINGULAIR—for your next appropriate patient with symptoms of allergic rhinitis

Think differently about relief
Help eligible patients save
This fall allergy season think differently about relief

SINGULAIR works differently—
blocks leukotrienes, an underlying cause of allergy symptoms.

Learn more about leukotrienes and allergic rhinitis.
Allergy Symptom Relief

SINGULAIR significantly reduced daytime nasal symptoms score

For adults

  • Seasonal allergic rhinitis
  • Perennial allergic rhinitis

Learn more about the
efficacy of SINGULAIR

SINGULAIR offers an established safety profile with patients with allergic rhinitis

For pediatric and
adolescent patients

Indicated for relief of symptoms in patients as
young as:

  • 6 months with perennial
    allergic rhinitis
  • 2 years with seasonal
    allergic rhinitis

Learn more about the
safety of SINGULAIR

For adults For Pediatric and Adolescent Patients

†In a placebo- and active-controlled clinical study of patients aged ≥15 years with seasonal and perennial
allergic rhinitis.

SINGULAIR is indicated for relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and children aged 2 years and older and perennial allergic rhinitis in adults and children aged 6 months and older).

SELECTED SAFETY INFORMATION

  • Neuropsychiatric events have been reported in patients taking SINGULAIR. These events included agitation, aggressive behavior or hostility, anxiousness, depression, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some postmarketing reports appear consistent with a drug-induced effect. Patients should be advised to report any neuropsychiatric events.
  • In clinical trials in patients with allergic rhinitis, adverse events varied by age. The most commonly reported adverse events, occurring at a frequency of >1% and at an incidence greater than placebo, regardless of causality assessment, were sinusitis, upper respiratory infection, sinus headache, cough, epistaxis, headache, otitis media, pharyngitis, and increased ALT.
  • SINGULAIR is contraindicated in patients with hypersensitivity to any component of this product.

Before prescribing SINGULAIR, please read the Prescribing Information.

20951837(3)-02/10-SNG

For general information and other services for physicians

Merck Services Merck OnCall

SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.